Immunohistologic analysis of estrogen receptor expression in breast carcinoma precursor lesions

Daniel W Visscher, Niru Padiyar, Dan Long, Pam Tabaczka

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The growth of invasive breast carcinoma is facilitated by abnormal expression of estrogen receptor (ER), however, the status of ER during disease histogenesis is poorly defined. The extent of ER immunostaining (expressed as percentage of positive cells) was semiquantitated in the invasive (ICA) and corresponding in situ (CIS) components of 50 formalin- fixed, paraffin-embedded breast carcinomas and then compared to staining in normal terminal duct lobular units (TDLU) or hyperplastic lesions (if present) in the same tissue sections. Morphologically normal TDLUs from most cases (61%) exhibited ER staining in 11-30% of epithelial cells; only 10% of the cases had TDLUs demonstrating immunoreactivity in more than 50% of cells. In contrast, 80% of the hyperplastic lesions showed ER staining in more than 30% of epithelial cells, with 44% demonstrating immunoreactivity in more than 50% of epithelial cell nuclei (p = 0.01, chi-square test). Although most in situ carcinomas showed even more extensive ER staining than hyperplasias (>70% of cells were positive in 50% of cases), a significant subset (28%) of CIS exhibited staining in less than 10% of cells (p = 0.002, chi-square test). Invasive carcinomas were less often extensively immunoreactive (i.e., >50% of cells positive) than CIS (32% versus 58% for CIS) and there were five cases (10%) in which the CIS component was ER positive but the invasive component was ER negative. Finally, ER-positive carcinomas were significantly more often accompanied by extensive CIS and/or proliferative breast disease (p = 0.007 and 0.003, respectively). The divergent levels of ER expression observed between premalignant, preinvasive, and invasive lesions suggests that inappropriate regulation of hormone receptors may be a factor that promotes early growth or progression in breast neoplasia, and ER-positive breast carcinomas are characterized by a different, possibly lengthier, histogenesis than ER-negative malignancies with a greater frequency of background hyperplastic lesions and a larger preinvasive component.

Original languageEnglish (US)
Pages (from-to)447-451
Number of pages5
JournalBreast Journal
Volume4
Issue number6
StatePublished - 1998
Externally publishedYes

Fingerprint

Estrogen Receptors
Breast Neoplasms
Staining and Labeling
Epithelial Cells
Chi-Square Distribution
Carcinoma
Breast Diseases
Carcinoma in Situ
Growth
Cell Nucleus
Paraffin
Formaldehyde
Hyperplasia
Neoplasms
Breast
Hormones

Keywords

  • Breast carcinoma
  • Estrogen receptor
  • Proliferative breast disease

ASJC Scopus subject areas

  • Internal Medicine
  • Oncology

Cite this

Immunohistologic analysis of estrogen receptor expression in breast carcinoma precursor lesions. / Visscher, Daniel W; Padiyar, Niru; Long, Dan; Tabaczka, Pam.

In: Breast Journal, Vol. 4, No. 6, 1998, p. 447-451.

Research output: Contribution to journalArticle

Visscher, Daniel W ; Padiyar, Niru ; Long, Dan ; Tabaczka, Pam. / Immunohistologic analysis of estrogen receptor expression in breast carcinoma precursor lesions. In: Breast Journal. 1998 ; Vol. 4, No. 6. pp. 447-451.
@article{8cd0f6295f914173971e67696618f1ae,
title = "Immunohistologic analysis of estrogen receptor expression in breast carcinoma precursor lesions",
abstract = "The growth of invasive breast carcinoma is facilitated by abnormal expression of estrogen receptor (ER), however, the status of ER during disease histogenesis is poorly defined. The extent of ER immunostaining (expressed as percentage of positive cells) was semiquantitated in the invasive (ICA) and corresponding in situ (CIS) components of 50 formalin- fixed, paraffin-embedded breast carcinomas and then compared to staining in normal terminal duct lobular units (TDLU) or hyperplastic lesions (if present) in the same tissue sections. Morphologically normal TDLUs from most cases (61{\%}) exhibited ER staining in 11-30{\%} of epithelial cells; only 10{\%} of the cases had TDLUs demonstrating immunoreactivity in more than 50{\%} of cells. In contrast, 80{\%} of the hyperplastic lesions showed ER staining in more than 30{\%} of epithelial cells, with 44{\%} demonstrating immunoreactivity in more than 50{\%} of epithelial cell nuclei (p = 0.01, chi-square test). Although most in situ carcinomas showed even more extensive ER staining than hyperplasias (>70{\%} of cells were positive in 50{\%} of cases), a significant subset (28{\%}) of CIS exhibited staining in less than 10{\%} of cells (p = 0.002, chi-square test). Invasive carcinomas were less often extensively immunoreactive (i.e., >50{\%} of cells positive) than CIS (32{\%} versus 58{\%} for CIS) and there were five cases (10{\%}) in which the CIS component was ER positive but the invasive component was ER negative. Finally, ER-positive carcinomas were significantly more often accompanied by extensive CIS and/or proliferative breast disease (p = 0.007 and 0.003, respectively). The divergent levels of ER expression observed between premalignant, preinvasive, and invasive lesions suggests that inappropriate regulation of hormone receptors may be a factor that promotes early growth or progression in breast neoplasia, and ER-positive breast carcinomas are characterized by a different, possibly lengthier, histogenesis than ER-negative malignancies with a greater frequency of background hyperplastic lesions and a larger preinvasive component.",
keywords = "Breast carcinoma, Estrogen receptor, Proliferative breast disease",
author = "Visscher, {Daniel W} and Niru Padiyar and Dan Long and Pam Tabaczka",
year = "1998",
language = "English (US)",
volume = "4",
pages = "447--451",
journal = "Breast Journal",
issn = "1075-122X",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Immunohistologic analysis of estrogen receptor expression in breast carcinoma precursor lesions

AU - Visscher, Daniel W

AU - Padiyar, Niru

AU - Long, Dan

AU - Tabaczka, Pam

PY - 1998

Y1 - 1998

N2 - The growth of invasive breast carcinoma is facilitated by abnormal expression of estrogen receptor (ER), however, the status of ER during disease histogenesis is poorly defined. The extent of ER immunostaining (expressed as percentage of positive cells) was semiquantitated in the invasive (ICA) and corresponding in situ (CIS) components of 50 formalin- fixed, paraffin-embedded breast carcinomas and then compared to staining in normal terminal duct lobular units (TDLU) or hyperplastic lesions (if present) in the same tissue sections. Morphologically normal TDLUs from most cases (61%) exhibited ER staining in 11-30% of epithelial cells; only 10% of the cases had TDLUs demonstrating immunoreactivity in more than 50% of cells. In contrast, 80% of the hyperplastic lesions showed ER staining in more than 30% of epithelial cells, with 44% demonstrating immunoreactivity in more than 50% of epithelial cell nuclei (p = 0.01, chi-square test). Although most in situ carcinomas showed even more extensive ER staining than hyperplasias (>70% of cells were positive in 50% of cases), a significant subset (28%) of CIS exhibited staining in less than 10% of cells (p = 0.002, chi-square test). Invasive carcinomas were less often extensively immunoreactive (i.e., >50% of cells positive) than CIS (32% versus 58% for CIS) and there were five cases (10%) in which the CIS component was ER positive but the invasive component was ER negative. Finally, ER-positive carcinomas were significantly more often accompanied by extensive CIS and/or proliferative breast disease (p = 0.007 and 0.003, respectively). The divergent levels of ER expression observed between premalignant, preinvasive, and invasive lesions suggests that inappropriate regulation of hormone receptors may be a factor that promotes early growth or progression in breast neoplasia, and ER-positive breast carcinomas are characterized by a different, possibly lengthier, histogenesis than ER-negative malignancies with a greater frequency of background hyperplastic lesions and a larger preinvasive component.

AB - The growth of invasive breast carcinoma is facilitated by abnormal expression of estrogen receptor (ER), however, the status of ER during disease histogenesis is poorly defined. The extent of ER immunostaining (expressed as percentage of positive cells) was semiquantitated in the invasive (ICA) and corresponding in situ (CIS) components of 50 formalin- fixed, paraffin-embedded breast carcinomas and then compared to staining in normal terminal duct lobular units (TDLU) or hyperplastic lesions (if present) in the same tissue sections. Morphologically normal TDLUs from most cases (61%) exhibited ER staining in 11-30% of epithelial cells; only 10% of the cases had TDLUs demonstrating immunoreactivity in more than 50% of cells. In contrast, 80% of the hyperplastic lesions showed ER staining in more than 30% of epithelial cells, with 44% demonstrating immunoreactivity in more than 50% of epithelial cell nuclei (p = 0.01, chi-square test). Although most in situ carcinomas showed even more extensive ER staining than hyperplasias (>70% of cells were positive in 50% of cases), a significant subset (28%) of CIS exhibited staining in less than 10% of cells (p = 0.002, chi-square test). Invasive carcinomas were less often extensively immunoreactive (i.e., >50% of cells positive) than CIS (32% versus 58% for CIS) and there were five cases (10%) in which the CIS component was ER positive but the invasive component was ER negative. Finally, ER-positive carcinomas were significantly more often accompanied by extensive CIS and/or proliferative breast disease (p = 0.007 and 0.003, respectively). The divergent levels of ER expression observed between premalignant, preinvasive, and invasive lesions suggests that inappropriate regulation of hormone receptors may be a factor that promotes early growth or progression in breast neoplasia, and ER-positive breast carcinomas are characterized by a different, possibly lengthier, histogenesis than ER-negative malignancies with a greater frequency of background hyperplastic lesions and a larger preinvasive component.

KW - Breast carcinoma

KW - Estrogen receptor

KW - Proliferative breast disease

UR - http://www.scopus.com/inward/record.url?scp=0032417681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032417681&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 447

EP - 451

JO - Breast Journal

JF - Breast Journal

SN - 1075-122X

IS - 6

ER -